ReviewEndocrine connections2018
On type 1 diabetes mellitus pathogenesis.
Review in Endocrine connections, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07194291 (Menstrual Cycle Changes in Adolescent Girls With Diabetes), which is not on this map. Cited by 110 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Menstrual Cycle Changes in Adolescent Girls With Diabetes
Who cites it
110 citing papers in PubMed, 2 syntheses or guidelines pooled it, 255 citations in OpenAlex.
- Vitamin D Deficiency as a Possible Cause of Type 1 Diabetes in Children and Adolescents up to 15 Years Old: A Systematic Review.The review of diabetic studies : RDS · 2022Pooled it
- Vitamin D and Type 1 Diabetes Risk: A Systematic Review and Meta-Analysis of Genetic Evidence.Nutrients · 2021Pooled it
- A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes.Diabetologia · 2021Trial
- Long-term (52-week) efficacy and safety of ipragliflozin add-on therapy to insulin in Japanese patients with type 1 diabetes mellitus: An uncontrolled, open-label extension of a phase III study.Journal of diabetes investigation · 2020Trial
- Efficacy and safety of ipragliflozin add-on therapy to insulin in Japanese patients with type 1 diabetes mellitus: A randomized, double-blind, phase 3 trial.Diabetes, obesity & metabolism · 2019Trial
- Functional Vestibular Abilities in Children and Adolescents With and Without Type 1 Diabetes Mellitus: Preliminary Results.Laryngoscope investigative otolaryngology · 2026Article
- Impaired Bone Density and Quality in Type 1 Diabetes Mellitus: Prevalence and Key Clinical Correlations.Journal of clinical medicine · 2026Article
- The effect(s) of berberine fromIranian journal of basic medical sciences · 2026Article
- Article
- The Chemistry of Gliflozins: Recent Advancements in SGLT-2 Inhibitors.Cardiovascular & hematological agents in medicinal chemistry · 2026Review
- The therapeutic potential of mesenchymal stem cells-derived extracellular vesicles/exosomes on the diabetes: a systematic review study.Diabetology & metabolic syndrome · 2025Review
- Nanoliposome-based drug delivery systems for the treatment of diabetes mellitus: a review.RSC advances · 2025Review
- Effects of Silver Nanoparticle-Loaded 18β-Glycyrrhetinic Acid on P2X7 Receptor and Endoplasmic Reticulum Stress-Mediated NLRP3 Inflammasome Activation in Testicular Tissue in an Animal Diabetes Model.Food science & nutrition · 2025Article
- Unravelling the role of natural herbs for the management of diabetes mellitus.Diabetology & metabolic syndrome · 2025Review
- Young Healthy Individuals With a First-Degree Relative With Type 1 Diabetes Displayed Adverse Lipid Changes.Acta paediatrica (Oslo, Norway : 1992) · 2025Article
- Post-COVID Metabolic Fallout: A Growing Threat of New-Onset and Exacerbated Diabetes.Biomedicines · 2025Review
- Type 1 Diabetes Mellitus and Vitamin D.International journal of molecular sciences · 2025Review
- Active targeting of type 1 diabetes therapies to pancreatic beta cells using nanocarriers.Diabetologia · 2025Review
- Tailoring Exercise Prescription for Effective Diabetes Glucose Management.The Journal of clinical endocrinology and metabolism · 2025Review
- Unveiling the Therapeutic Potential of the Second-Generation Incretin Analogs Semaglutide and Tirzepatide in Type 1 Diabetes and Latent Autoimmune Diabetes in Adults.Journal of clinical medicine · 2025Review
50 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 1 diabetes mellitus (T1DM) results from the autoimmune destruction of β cells of the endocrine pancreas. Pathogenesis of T1DM is different from that of type 2 diabetes mellitus, where both insulin resistance and reduced secretion of insulin by the β cells play a synergistic role. We will present genetic, environmental and immunologic factors that destroy β cells of the endocrine pancreas and lead to insulin deficiency. The process of autoimmune destruction takes place in genetically susceptible individuals under the triggering effect of one or more environmental factors and usually progresses over a period of many months to years, during which period patients are asymptomatic and euglycemic, but positive for relevant autoantibodies. Symptomatic hyperglycemia and frank diabetes occur after a long latency period, which reflects the large percentage of β cells that need to be destroyed before overt diabetes become evident.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.